Surface Oncology Announces Appointment of F. Stephen Hodi, MD to its Scientific Advisory Board
January 04 2019 - 7:00AM
Surface Oncology (Nasdaq: SURF), a clinical-stage
immuno-oncology company developing next-generation immunotherapies
that target the tumor microenvironment, today announced the
appointment of the F. Stephen Hodi, MD to the company’s scientific
advisory board (SAB).
“Surface Oncology continues to grow and learn as
a company and we look to align ourselves with world-class leaders
in the fields of oncology and immunology. Steve is a clinical
pioneer in the field of cancer immunotherapy. His groundbreaking
work in melanoma with checkpoint inhibitors led to the first wave
of cancer immunotherapy drug approvals. We are thrilled Steve has
agreed to join our world-class scientific advisory board and look
forward to his clinical and scientific insights,” said Vito
Palombella PhD, chief scientific officer of Surface
Oncology.
Dr. Hodi is Director of the Melanoma Center and
the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s
Cancer Center, the Sharon Crowley Martin Chair in Melanoma at
Dana-Farber Cancer Institute, and Professor of Medicine at Harvard
Medical School. He received his MD degree from Cornell University
Medical College. Dr. Hodi completed his postdoctoral training in
Internal Medicine at the Hospital of the University of
Pennsylvania, and Medical Oncology training at Dana-Farber Cancer
Institute. His research focuses on the development of immune
therapies, and first into human studies for malignant melanoma. Dr.
Hodi is a member of the American Society of Clinical Oncology, the
Eastern Cooperative Oncology Group Melanoma Committee, the Society
for Immunotherapy of Cancer, and a founding member of the Society
for Melanoma Research.
“I am excited to have the opportunity to
collaborate with the team at Surface Oncology. Surface’s goal of
targeting the immunosuppressive tumor microenvironment has produced
a unique portfolio of programs,” said Dr. Hodi. “I look forward to
working with the team to help move these programs through clinical
development, identify additional novel targets to pursue, and to
make a meaningful impact for patients.”
ABOUT SURFACE ONCOLOGY
Surface Oncology is an immuno-oncology
company developing next-generation antibody therapies focused on
the tumor microenvironment with lead programs targeting CD73, CD39,
IL-27 and CD47. Surface’s novel cancer immunotherapies are designed
to achieve a clinically meaningful and sustained anti-tumor
response and may be used alone or in combination with other
therapies. The company has a pipeline of seven novel
immunotherapies and a strategic collaboration
with Novartis focused on up to three next-generation
cancer immunotherapies.
For more information, please
visit www.surfaceoncology.com
Contacts:Seth
Lewisslewis@surfaceoncology.com617-655-5031
Ten Bridge CommunicationsKrystle
Gibbskrystle@tenbridgecommunications.com508-479-6358
Surface Oncology (NASDAQ:SURF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Surface Oncology (NASDAQ:SURF)
Historical Stock Chart
From Sep 2023 to Sep 2024